Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X:
“Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With TNBC With Brain Metastases (ABC Study)
Looks like this one slipped past the Journal of Clinical Oncology production team.
Returning to the paper: CNS-PFS was 10.3 mo, and OS was 21.1 mo.”
Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared Yakup Ergün’s post, adding:
“Very excited about bringing VEGF bispecifics into the brain mets space. This builds off Nancy Lin data with Carbo and Bev showing CNS ORR of > 60%.
Pseudo response is real necessitating CNS-PFS as a complementary end point.”
Title: Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
Authors: Ting Li, Teng Zhou, Biyun Wang, Zhonghua Tao, Mingchuan Zhao, Leiping Wang, Juan Jin, Yannan Zhao, Chengcheng Gong, Jun Cao, Haotao Miao, Wenxia Peng, Jianfei Wang, Min Jin, Xichun Hu, Jian Zhang
Read the Full Article.
Other articles featuring Yakup Ergün on OncoDaily.
